What is the Best Approach for Treatment of Hormone Positive/HER Positive Advanced Breast Cancer?

The prognosis of patients with metastatic HER positive disease was improved by the anti-HER targeted therapies. Approximatively, 10% of all breast cancers are both HER2 positive and hormone receptor positive [1]. The optimal management of hormone positive/HER positive metastatic breast cancer (MBC) remains unclear The NCCN guidelines recommend first line endocrine therapy regardless of HER status excepted